Cancer investigation

publication venue for

Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report. 1996
Allogeneic marrow transplantation for myelodysplastic syndrome complicating autologous bone marrow transplantation. 1994
Fatal thrombocytopenia and liver failure associated with carboplatin therapy. 1991
Epstein--Barr virus nuclear antigen in a non-Hodgkin's lymphoma. 1984
Localized renal aspergillosis with hairy cell leukemia: a review of urinary tract aspergillosis in malignant and nonmalignant conditions. 1984
Tumor Inhibition by Enzalutamide in a Xenograft Model of Ovarian Cancer.. 34. 2016
Predictors of Interventional Treatment Use for Venous Thromboembolism in Cancer Patients.. 34. 2016
Safety, Utilization, and Cost of Image-Guided Percutaneous Liver Biopsy Among Cancer Patients.. 34. 2016
Does the Presence of Endometriosis Affect Prognosis of Ovarian Cancer?. 34. 2016
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer.. 32. 2014
Routine histopathologic characteristics can predict oncotype DX(TM) recurrence score in subsets of breast cancer patients.. 31. 2013
Prognostic significance of mucinous differentiation of endometrioid adenocarcinoma of the endometrium.. 31. 2013
The numbers of FoxP3+ lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status.. 29. 2011
Obesity and microvascular invasion in hepatocellular carcinoma.. 28. 2010
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.. 27. 2009
The risk of hepatocellular carcinoma in patients with previous malignancy.. 26. 2008
Computer visualization techniques (CVTs) foster evidence-based target delineation.. 25. 2007
A Phase I dose-finding study using an innovative sequential biweekly schedule of irinotecan followed 24 hours later by capecitabine.. 25. 2007
Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma.. 24. 2006
Iron absorption during epoetin alfa therapy for chemotherapy-associated anaemia.. 24. 2006
Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin.. 24. 2006
Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer.. 23. 2005
Tumor motion control in the treatment of non small cell lung cancer.. 23. 2005
HER-2/neu and p53 in osteosarcoma: an immunohistochemical and fluorescence in situ hybridization analysis.. 22. 2004
Arterial desaturation syndrome following pleurodesis with talc slurry: incidence, clinical features, and outcome.. 21. 2003
Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.. 21. 2003
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.. 20. 2002
Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control.. 20. 2002
Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer.. 18. 2000
A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.. 17. 1999
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.. 16. 1998
Phase II trial of docetaxel (Taxotere) for untreated advanced colorectal carcinoma.. 16. 1998
Phase II trial of paclitaxel in patients with soft-tissue sarcoma.. 16. 1998
Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation.. 15. 1997
Insulin-like growth factor I receptor messenger RNA in the colon is unchanged during neoplasia.. 15. 1997
A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia.. 13. 1995
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer.. 13. 1995
Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma.. 12. 1994
Preselection of patients with high TAG-72 antigen expression leads to targeting of 94% of known metastatic tumor sites with monoclonal antibody I-131-CC49.. 12. 1994
Seroprevalence of human T-lymphotropic virus in blacks from a selected central Brooklyn population.. 12. 1994
An intensive sequenced adjuvant chemotherapy regimen for breast cancer.. 11. 1993
Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake.. 11. 1993
Patient awareness under general anesthesia.. 11. 1993
Alterations in self-perceptions among adolescent cancer survivors.. 9. 1991
A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443.. 8. 1990
A phase I trial of combination chemotherapy employing carboplatin, vinca alkaloids, with or without bleomycin in patients with advanced malignant tumors.. 8. 1990
Phase I trial of PALA, methotrexate, fluorouracil, leucovorin, and uridine rescue in patients with advanced cancer. The use of uridine to decrease fluorouracil toxicity.. 8. 1990
In vitro chemopurification of neuroblastoma cells: comparison of 6-hydroxydopamine and ascorbic acid with 4-hydroperoxycyclophosphamide.. 7. 1989
In vitro chemosensitivity of two Ewing's sarcoma cell lines: implication for autologous bone marrow transplantation.. 7. 1989
Attempted prevention of blast crisis in chronic myeloid leukemia by the use of pulsed doses of cytosine arabinoside and cis-chloronitrosurea during the course of busulfan-maintained remission.. 6. 1988
Systemic absorption of a leucovorin mouth wash: a pharmacologic study.. 5. 1987
Growth and development of children born to patients after cancer therapy.. 4. 1986
Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.. 3. 1985
Intravenous usage of gammaglobulin: humoral immunodeficiency, immune thrombocytopenic purpura, and newer indications.. 3. 1985
Phase I study of elliptinium (2-N-methyl-9-hydroxyellipticinium).. 3. 1985
Primary osteogenic sarcoma of the femur: a model for the use of preoperative chemotherapy in high risk malignant tumors.. 2. 1984
Controversies in the management of breast cancer: one radiotherapist's view.. 1. 1983
Predictive factors in prostate cancer: implications for decision making. 2003
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor. 2004
Dose-volume histograms can be interpreted in different ways. 1997
The emerging role of neoadjuvant hormonal therapy in the management of localized prostatic cancer--reply. 1997
Re: "We may be lost, but we're sure makin' good time". 1994
The meaning of translation.. 24. 2006
Editorial on a phase I study on combined modality therapy in esophageal cancer.. 22. 2004
A hope for the future.. 21. 2003
Treatment of sarcomas: thinking out-of-the-box.. 21. 2003
Dendritic cell vaccines--hopeful or hopeless?. 21. 2003
Soy: an anticancer agent in wide use despite some troubling data.. 21. 2003
Estramustine plus a taxane for advanced prostate cancer: the new standard therapy?. 20. 2002
Pediatric AML: past, present, and future.. 20. 2002
A new intensified therapeutic regimen for advanced head and neck squamous cell carcinomas: where does it fit among available treatment options?. 19. 2001
High-dose chemotherapy with autologous stem cell rescue for malignant brain tumors.. 18. 2000
Decision to operate, radiate, or watch and wait: the prostate cancer dilemma.. 17. 1999
Primary non-Hodgkin's lymphoma of bone.. 16. 1998
RIGS: surgery. Talking the talk and (just possibly) walking the walk.. 14. 1996
Chemotherapy in locally advanced, squamous cell head and neck cancer: limitations, lessons learned, and evolving standards of care.. 13. 1995
A model for others: a strategy for improving diagnosis and therapy of human malignancies using monoclonal antibodies targeting TAG-72 oncofetal antigen.. 11. 1993
The current status of salvage chemotherapy for patients with cisplatin-resistant germ cell tumors.. 11. 1993
Improving the "quality of remission induction" therapy: a necessary step for increasing the cure rate in acute myelogenous leukemia.. 10. 1992
BOMM: new solution or old problem?. 9. 1991
First reports from unexplored seas: radiolabeled antibodies and cancer.. 8. 1990
Peaks, valleys, and plateaus in small cell lung cancer.. 6. 1988
Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis. 2017
Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer. 2016
Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients. 2015
The role of environmental factors in the etiology of lymphoma. 2008
Renaming "chemobrain". 2007
The role of aggressive regional therapy for colorectal liver metastases. 2007
Disialoganglioside directed immunotherapy of neuroblastoma. 2007
Pharmacogenomics of colorectal cancer prevention and treatment. 2006
Leptomeningeal metastasis. 2005
Pain in cancer patients unrelated to the cancer or treatment. 2005
Intensity modulated radiation therapy (IMRT) in the management of prostate cancer. 2004
Progress report on the potential of angiogenesis inhibitors for neuro-oncology. 2004
Surgical management of hepatic malignancy. 2004
STI571 as a targeted therapy for CML. 2003
Comparative physical and pharmacologic characteristics of iodine-131 and yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. 2003
Apoptosis in lymphocytic leukemias and lymphomas. 2002
Botanical medicines for the treatment of cancer: rationale, overview of current data, and methodological considerations for phase I and II trials. 2002
Critical review of current treatment strategies for advanced hormone insensitive breast cancer. 2002
Melanoma vaccines. 2002
Cognitive effects of standard-dose chemotherapy in patients with cancer. 2001
Renal cell carcinoma and interferon at the millennium. 2001
Role of angiogenesis in the progression and treatment of prostate cancer. 2001
Silicone breast implants and cancer. 2001
The role of CXC chemokines in the regulation of tumor angiogenesis. 2001
Psychosexual adjustment in adolescent cancer survivors. 2000
Advances in magnetic resonance imaging: applications in body imaging. 1998
Pathophysiology and management of bone disease in multiple myeloma. 1997
The biological therapy of acute and chronic leukemia. 1997
Stereotactic radiosurgery for primary and metastatic brain tumors. 1996
The case for adjuvant radiation therapy in advanced Hodgkin's disease. 1996
Growth following therapy for childhood cancer. 1995
Blood progenitor cells: collection techniques and applications. 1994
Clinical progress in neuroblastoma. 1994
Limb-sparing surgery for extremity sarcoma. 1994
Management of brain metastases. 1994
Edatrexate, an antifolate with antitumor activity: a review. 1993
Hyperthermic isolation limb perfusion for malignant melanoma: a review. 1992
Immune senescence: mechanisms and clinical implications. 1992
Chemotherapy of metastatic Merkel cell cancer. 1991
Insulinlike growth factors in human malignancy. 1991
A review of the management of germ cell tumors: evolution of a curative treatment program. 1990
Corticosteroids in cancer: neuropsychiatric complications. 1989
Implications of growth kinetic concepts for cancer chemoprevention. 1988
Controversies in treatment of small cell carcinoma of the lung. 1985
Radioimmunodetection and radioimmunotherapy. 1984
Prostaglandins in cancer: a review. 1983

VIVO Weill Cornell Medical College

Cancer investigation Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)